ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer

Chang, Jianhua; Wu, Yi-Long; Lu, Shun; Wang, Jie; Mok, Tony; Zhang, Li; Feng, Jifeng; Wu, Lin; Tu, Hai-Yan; Zhang, Yiping; Luft, Alexander; Zhou, Jian-ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Penrod, John R.; Taylor, Fiona; Lawrance, Rachael; Blum, Steven, I; Sun, Xiaowu; Juarez-Garcia, Ariadna; Moreno-Koehler, Alejandro; Li, Ang; Li, Amy; Cheng, Ying*复旦大学; 广东省人民医院; 四川大学; 郑州大学; 中国医学科学院; 中山大学; 中国医学科学院北京协和医院; 1; y
Lung Cancer2022-3DOI: 10.1016/j.lungcan.2021.12.009
8被引14阅读
引用收藏
分享

摘要

Objectives: In the phase 3 CheckMate 078 study, nivolumab prolonged overall survival (OS) and showed a favorable safety profile versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (aNSCLC). However, long-term efficacy, safety, and health-related quality of life findings with second-line nivolumab are very limited in Asian patients with previously treated aNSCLC. Here,we report updated clinical data and patient-reported outcomes (PROs) from the phase 3 CheckMate 078 trial with a 3-year minimum follow-up. @@@ Materials and methods: Patients with aNSCLC and disease progression after platinum-doublet chemotherapy were randomized 2:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m(2) every 3 weeks) until progression or unacceptable toxicity. The primary endpoint was OS; secondary endpoints included objective response rate, progression-free survival, safety, and disease-related symptom deterioration assessed using the Lung Cancer Symptom Scale (LCSS) by Week 12. Additional PRO assessments were exploratory endpoints. @@@ Results: At >= 37.3 months follow-up, 3-year OS rates were 19% with nivolumab and 12% with docetaxel; 30% and 0% of responders remained in response for >= 3 years, respectively. Incidence of treatment-related adverse events occurring after 2 years was lower than during the first 2 years. No new treatment-related deaths were reported. By Week 12 of treatment, rates of disease-related symptom deterioration were 32% with nivolumab and 47% with docetaxel. Completion rates for PRO questionnaires were >= 80% in both arms. Clinically meaningful and sustained improvements in LCSS Average Symptom Burden Index scores and delayed time to first symptom deterioration were observed with nivolumab against docetaxel. @@@ Conclusions: At 3 years, nivolumab continued to demonstrate survival benefit versus docetaxel, exhibiting improvements in disease-related symptoms and overall health status in a predominantly Chinese patient population with previously treated aNSCLC. No new safety signals were observed. These findings are similar to the global population.

学科与关键词

关键词
Advanced non-small cell lung cancerPD-1 checkpoint inhibitorNivolumabPatient-reported outcomesAsianSecond-line treatment
相关
加载中…
  • Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
    Lu, Shun; Wang, Jie; Cheng, Ying; Mok, Tony; Chang, Jianhua; Zhang, Li; Feng, Jifeng; Tu, Hai-Yan; Wu, Lin; Zhang, Yiping; Luft, Alexander; Zhou, Jian-Ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Ying, Kejing; Zhong, Hua; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Li, Ang; Li, Amy; Wu, Yi-Long*Lung Cancer, 2021, 152: 7-14.被引 35
  • An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
    Lu, Shun*; Cheng, Ying; Zhou, Jianying; Wang, Mengzhao; Zhao, Jun; Wang, Baocheng; Chen, Gongyan; Feng, Jifeng; Ma, Zhiyong; Wu, Lin; Wang, Changli; Ma, Kewei; Zhang, Shucai; Liang, Jun; Song, Yong; Wang, Jie; Wu, Yi-Long; Li, Ang; Huang, Yizhi; Chang, JianhuaTherapeutic Advances in Medical Oncology, 2022, 14.被引 2
  • Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results
    Lu, S.; Cheng, Y.; Zhou, J.; Wang, M.; Zhao, J.; Wang, B.; Chen, G.; Feng, J.; Ma, Z.; Wu, L.; Wang, C.; Ma, K.; Zhang, S.; Liang, J.; Song, Y.; Wang, J.; Wu, Y-L.; Li, A.; Huang, Y.; Chang, J.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.
查看全部 →

发表信息

论文状态
公开发表
期刊
Lung Cancer
发表日期
2022-03
卷期
第 165 卷
页码
71-81
DOI
10.1016/j.lungcan.2021.12.009
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Bristol Myers Squibb - Bristol Myers Squibb

作者

  • C

    Chang, Jianhua (第一作者)

    fudan univ

  • W

    Wu, Yi-Long

    guangdong prov peoples hosp

查看全部 29 位作者收起作者
  • L

    Lu, Shun

  • W

    Wang, Jie

    chinese acad med sci · peking union med coll

  • M

    Mok, Tony

    chinese univ hong kong

  • Z

    Zhang, Li

    sun yat sen univ

  • F

    Feng, Jifeng

  • W

    Wu, Lin

    hunan canc hosp

  • T

    Tu, Hai-Yan

    guangdong prov peoples hosp

  • Z

    Zhang, Yiping

    1 · zhejiang canc hosp

  • L

    Luft, Alexander

  • Z

    Zhou, Jian-ying

    1

  • M

    Ma, Zhiyong

    zhengzhou univ

  • L

    Lu, You

    sichuan univ

  • H

    Hu, Chengping

  • S

    Shi, Yuankai

    chinese acad med sci · peking union med coll

  • P

    Poddubskaya, Elena

  • S

    Soo, Ross A.

    1

  • C

    Chia, Yee Hong

  • P

    Penrod, John R.

  • T

    Taylor, Fiona

  • L

    Lawrance, Rachael

  • B

    Blum, Steven, I

  • S

    Sun, Xiaowu

  • J

    Juarez-Garcia, Ariadna

  • M

    Moreno-Koehler, Alejandro

  • L

    Li, Ang

  • L

    Li, Amy

  • C

    Cheng, Ying (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417